United Kingdom· GB-APID-4668711000001104
Kaletra 133.3mg/33.3mg capsules
A lopinavir and ritonavir product containing lopinavir + ritonavir, registered in United Kingdom by Abbott Laboratories Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Lopinavir and ritonavir is registered in 15 of 19 countries.
Countries holding a registration under ATC J05AR10 (lopinavir and ritonavir), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 10 of them publish a price we can compare per daily dose
Lopinavir and ritonavir · ATC J05AR10
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of lopinavir and ritonavir costs, country by country.
Normalised to the WHO defined daily dose (0.8 g), the median price runs from $17.81 in Switzerland to $763.00 in France — a ×43 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Lopinavir and ritonavir · price per daily dose (0.8 g)
USD · FX 28 Sept 2026
- FR France$763.00
- CH Switzerland$17.81
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Lopinavir + Ritonavir
- Manufacturer
- Abbott Laboratories Ltd
- Country
- United Kingdom (GB)
- ATC code
- J05AR10
- ATC class
- Lopinavir and ritonavir
- Defined daily dose
- 0.8 g, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
136 interactions on record for lopinavir and ritonavir.
Graded by severity as the source publishes them — 17 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Lopinavir and ritonavir · interactions on record
136 records
- 17 severe
- 71 moderate
- 7 minor
Most severe, free to view
- PapaverineA03AD01severe
- DolasetronA04AA04severe
- PapaverinC04AX38severe
- RosuvastatinC10AA07severe
41 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Lopinavir and ritonavir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKaletraAbbVie Inc.
- CzechiaKALETRAAbbVie Deutschland GmbH & Co.KG, Ludwigshafen
- FinlandKaletraAbbVie Deutschland GmbH&Co.KG
- SpainKALETRA (80 MG + 20 MG)/ML SOLUCION ORALAbbvie Deutschland Gmbh & Co. Kg
- NetherlandsKaletra (80 mg + 20 mg) /ml drankAbbVie Deutschland GmbH & Co. KG
- IrelandKaletraAbbVie Deutschland GmbH & Co. KG
- FranceKALETRA (80 mg + 20 mg)/ml, solution buvableABBVIE DEUTSCHLAND (ALLEMAGNE)
- IcelandKaletraAbbVie Deutschland GmbH & Co. KG
Authorised across Europe · EMA
The same active substance is authorised in 11 EEA countries. Names it is sold under:
- Estonia · Lopinavir/Ritonavir Ranbaxy, Lopinavir/Ritonavir Sun
- Spain · Lopinavir / Ritonavir Accord
- France · Lopinavir/Ritonavir Dextreg
- Iceland · Kaletra, Lopinavir/Ritonavir Mylan
- Liechtenstein · Kaletra, Lopinavir/Ritonavir Viatris
- Lithuania · Lopinavir / Ritonavir Sun, Lopinavir /Ritonavir Ranbaxy
- Latvia · Lopinavir/ Ritonavir Ranbaxy, Lopinavir/ Ritonavir Sun
- Netherlands · Lopinavir/Ritonavir Accord
- Norway · Kaletra, Lopinavir/Ritonavir Viatris
- Portugal · Lopinavir + Ritonavir Farmoz
- Slovenia · Lopinavir/Ritonavir Accord
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c2c21797-680c-4f19-939a-34a2882f2bf6 GET /v1/drugs/c2c21797-680c-4f19-939a-34a2882f2bf6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "4668711000001104",
"desc": "Kaletra 133.3mg/33.3mg capsules (Abbott Laboratories Ltd)",
"form": "Oral capsule",
"vpid": "41791211000001103",
"source": "dmd",
"vtm_id": "776569000",
"strength": "33.3 mg",
"substance": "Lopinavir + Ritonavir",
"ingredient": "Ritonavir",
"supplier_code": "2061801000001104"
}See everything about lopinavir and ritonavir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.